Literature DB >> 24997979

Post-treatment imaging changes in primary brain tumors.

Barbara J O'Brien1, Rivka R Colen.   

Abstract

Discerning between primary brain tumor progression and treatment-related effect is a significant issue and a major challenge in neuro-oncology. The difficulty in differentiating tumor progression from treatment-related effects has important implications for treatment decisions and prognosis, as well as for clinical trial design and results. Conventional MRI is widely used to assess disease status, but cannot reliably distinguish between tumor progression and treatment-related effects. Several advanced imaging techniques are promising, but have yet to be prospectively validated for this use. This review explores two treatment-related effects, pseudoprogression and radiation necrosis, as well as the concept of pseudoresponse, and highlights several advanced imaging modalities and the evidence supporting their use in differentiating tumor progression from treatment-related effect.

Entities:  

Mesh:

Year:  2014        PMID: 24997979     DOI: 10.1007/s11912-014-0397-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  63 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

2.  Discrimination between metastasis and glioblastoma multiforme based on morphometric analysis of MR images.

Authors:  L Blanchet; P W T Krooshof; G J Postma; A J Idema; B Goraj; A Heerschap; L M C Buydens
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-04       Impact factor: 3.825

3.  ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.

Authors:  Dong-Li Li; Yi-Kai Xu; Quan-Shi Wang; Hu-Bing Wu; Hong-Sheng Li
Journal:  Chin Med J (Engl)       Date:  2012-01       Impact factor: 2.628

4.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Authors:  P Kunkel; U Ulbricht; P Bohlen; M A Brockmann; R Fillbrandt; D Stavrou; M Westphal; K Lamszus
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

Authors:  Yaning Wang; David Fei; Martin Vanderlaan; An Song
Journal:  Angiogenesis       Date:  2005-05-09       Impact factor: 9.596

6.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

Authors:  June-Key Chung; Yu Kyeong Kim; Seok-ki Kim; Yong Jin Lee; Suntta Paek; Jeong Seok Yeo; Jae Min Jeong; Dong Soo Lee; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

Review 7.  The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas.

Authors:  P Sanghera; R Rampling; B Haylock; S Jefferies; C McBain; J H Rees; C Soh; I R Whittle
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-07-23       Impact factor: 4.126

8.  Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

Authors:  Rahul N Sawlani; Jeffrey Raizer; Sandra W Horowitz; Wanyong Shin; Sean A Grimm; James P Chandler; Robert Levy; Christopher Getch; Timothy J Carroll
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

9.  Improving brain tumor characterization on MRI by probabilistic neural networks and non-linear transformation of textural features.

Authors:  Pantelis Georgiadis; Dionisis Cavouras; Ioannis Kalatzis; Antonis Daskalakis; George C Kagadis; Koralia Sifaki; Menelaos Malamas; George Nikiforidis; Ekaterini Solomou
Journal:  Comput Methods Programs Biomed       Date:  2007-11-28       Impact factor: 5.428

Review 10.  Advances in MRI assessment of gliomas and response to anti-VEGF therapy.

Authors:  Whitney B Pope; Jonathan R Young; Benjamin M Ellingson
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

View more
  13 in total

Review 1.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

2.  Early imaging marker of progressing glioblastoma: a window of opportunity.

Authors:  Na Tosha N Gatson; Shane P Bross; Yazmin Odia; Gino J Mongelluzzo; Yirui Hu; Laura Lockard; Jesse J Manikowski; Anand Mahadevan; Syed A J Kazmi; Michel Lacroix; Andrew R Conger; Joseph Vadakara; Lakshmi Nayak; T Linda Chi; Minesh P Mehta; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2020-06-29       Impact factor: 4.130

3.  Late post-treatment radiographic changes 3 years following chemoradiation for glioma: the importance of histopathology.

Authors:  Joao R Galante; Fausto Rodriguez; Stuart A Grossman; Roy E Strowd
Journal:  CNS Oncol       Date:  2017-07-18

Review 4.  Epileptic seizure in primary intracranial sarcoma: a case report and literature review.

Authors:  Yen-Ping Chen; Hsiu-Fen Lee; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2016-07-12       Impact factor: 1.475

Review 5.  High-grade glioma management and response assessment-recent advances and current challenges.

Authors:  M N Khan; A M Sharma; M Pitz; S K Loewen; H Quon; A Poulin; M Essig
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

Review 6.  Magnetic resonance imaging patterns of treatment-related toxicity in the pediatric brain: an update and review of the literature.

Authors:  Maria Camilla Rossi Espagnet; Luca Pasquini; Antonio Napolitano; Antonella Cacchione; Angela Mastronuzzi; Roberta Caruso; Paolo Tomà; Daniela Longo
Journal:  Pediatr Radiol       Date:  2016-12-09

7.  Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism.

Authors:  Friederike Hesse; Alan J Wright; Vencel Somai; Flaviu Bulat; Felix Kreis; Kevin M Brindle
Journal:  Cancer Res       Date:  2022-10-04       Impact factor: 13.312

8.  Visual field changes as an early indicator of glioblastoma multiforme progression: two cases of functional vision changes before MRI detection.

Authors:  Kate Xie; Catherine Y Liu; Anton N Hasso; Robert Wade Crow
Journal:  Clin Ophthalmol       Date:  2015-06-11

9.  Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Authors:  Ovidiu C Andronesi; Morteza Esmaeili; Ronald J H Borra; Kyrre Emblem; Elizabeth R Gerstner; Marco C Pinho; Scott R Plotkin; Andrew S Chi; April F Eichler; Jorg Dietrich; S Percy Ivy; Patrick Y Wen; Dan G Duda; Rakesh Jain; Bruce R Rosen; Gregory A Sorensen; Tracy T Batchelor
Journal:  NPJ Precis Oncol       Date:  2017-06-12

10.  Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.

Authors:  Qian Xu; Qi Liu; Haitao Ge; Xinting Ge; Jiangfen Wu; Jianxun Qu; Kai Xu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.